申请人一直致力于生物药物靶向递送策略的研究。选择新型药物靶点，提出靶向递送策略，筛选特异性靶向配体，构建新型靶向递送系统，以期克服药物大分子在应用过程中特异性差、递送效率低等不足，为实现药物大分子的靶向递送奠定研究基础。申请人于2007年就职于美国密苏里大学堪萨斯分校。在此期间，荣获四次美国联邦政府经费支持、美国癌症协会研究学者经费支持和美国药学科学家学会新研究学者经费支持等，共计3,079,103美元。目前，发表文章共计44篇，撰写书稿章节若干。在此基础上，申请人拟利用噬菌体展示技术发现新型的靶向肽，利用合作者的聚合物缀合技术平台合成新型多功能材料，构建多功能的基因与药物靶向递送系统，从而实现前列腺癌的靶向治疗，以期提高前列腺癌的治疗效果。

The applicant focused on the development of biological drug targeted delivery strategy. Macromolecular drugs suffer from poor specificity and low drug delivery efficiency, which greatly restrict their further application. To achieve the targeting delivery of the macromolecular drugs, novel drug targets and specific targeting ligands were filtered, newly targeted drug delivery system was built in the applicant’s previous work. Since he joined UMKC in 2007, he has received four federal grants, American Cancer Society Research Scholar Grant, and American Association of Pharmaceutical Scientists (AAPS) New Investigator Grant (in a total amount of $3,079,103). He has published 44 peer-reviewed journal articles and book chapters. With this in mind, the applicant designed to use the phase display technology to find novel targeting peptide, utilize the conjugated polymer technology platform of the partner to synthesis novel multifunctional materials, and build multifunctional gene and drug co-delivery delivery system to achieve the targeting therapy and treatment effect of the prostate cancer.